Aktis Oncology (AKTS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
of free cash flow goes to stock comp (was −3.4% in FY22). Owner-earnings math treats it as a real cost.
34.9mn → 52.5mn diluted shares since FY22. Rising share count dilutes EPS. Growth must outrun it.
▲235% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
$0.0M returned vs $−73.7M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
-981¢ of every revenue dollar becomes profit.
Net margin -980.9% is below the sector median.
| Line item | FY25 | FY24 | FY23 | FY22 | YoY | CAGR 22→25 |
|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||
Revenue | 6.5 | 1.5 | 0.0 | 0.0 | ▲336.9% | — |
Cost of revenue | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 6.5 | 1.5 | 0.0 | 0.0 | ▲336.9% | — |
Research & development | 67.5 | 41.0 | 25.9 | 14.3 | ▲64.7% | +67.7% |
Selling, general & admin | 12.6 | 11.3 | 7.7 | 5.1 | ▲11.4% | +35.1% |
Total operating expenses | 81.2 | 53.5 | 34.8 | 19.8 | ▲51.6% | +60.1% |
Operating incomefeeds ROC rank | −74.7 | −52.0 | −34.8 | −19.8 | ▼43.5% | — |
Other income, net | 11.0 | 8.1 | 6.2 | 1.8 | — | — |
Pretax income | −63.7 | −44.0 | −28.6 | −17.9 | ▼44.9% | — |
Income tax | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −63.7 | −44.0 | −28.6 | −17.9 | ▼44.9% | — |
| Per share | ||||||
Diluted EPSbuyback-sensitive | −1.19 | −1.26 | −0.82 | −0.51 | ▲5.6% | — |
Diluted shares (mn) | 52.52 | 34.86 | 34.86 | 34.86 | ▲50.6% | +14.6% |
| Margins | ||||||
Gross margin82nd pct in Healthcare | 100.0% | 100.0% | — | — | ▲0.0pp | — |
Operating margin | −1149.5% | −3500.3% | — | — | ▲2350.8pp | — |
Net margin8th pct in Healthcare | −980.9% | −2957.6% | — | — | ▲1976.7pp | — |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Aktis Oncology's revenue last fiscal year?
Aktis Oncology reported revenue of $6.5M in fiscal 2025, up 336.9% from fiscal 2024.
What was Aktis Oncology's net income?
Aktis Oncology reported net income of −$63.7M in fiscal 2025, a net margin of −980.9%.

